Tuckson takes director post

Robeznieks, Andis
October 2011
Modern Healthcare;10/3/2011, Vol. 41 Issue 40, p16
Trade Publication
The article announces the appointment of Doctor Reed Tuckson, chief of medical affairs at Minnesota-based insurer, Minnetonka, to the board of directors for Cell Therapeutics, a Seattle, Washington-based manufacturer of oncology products.


Related Articles

  • The riches of e-prescribing. Vesely, Rebecca // Modern Healthcare;2/18/2008, Vol. 38 Issue 7, p6 

    The article discusses the reasons insurers are encouraging physicians in the U.S. to prescribe medications electronically. E-prescribing is defined as the usage of computer technology to write and transmit prescriptions between physicians and pharmacies. It has the potential to revolutionize...

  • Banner year for drug chains.  // Chain Store Age;Jan1999, Vol. 75 Issue 1, p37 

    Explains why 1998 was a banner year for the drug store industry in the United States. Sales of drug store chains according to the National Association of Chain Drug Stores; Total revenues of chain drug stores; Growth in the coming years; Prescription volume; Number of drug stores that has...

  • AMCP positions formulary tool as industry standard. Chi, Judy // Drug Topics;5/21/2001, Vol. 145 Issue 10, p53 

    Presents highlights of a meeting by the Academy of Managed Care Pharmacy (AMCP) in 2001. Information on the Format for Formulary Submissions developed by AMCP; Issues that pharmacies should address.

  • Rub-a-dub-dub, three PBMs in a 'Hub' Cohen, Harold E. // Drug Topics;6/18/2001, Vol. 145 Issue 12, p3 

    Analyzes why pharmacy benefit managers (PBMs) in the United States are moving forward to create a clearinghouse for the electronic trafficking of prescriptions from physician's offices. Three PBMs involved in the clearing house; Concept for the trafficking; Investment of companies.

  • Prescribing update. Saunders, Carol S. // Patient Care;9/30/2000, Vol. 34 Issue 18, p10 

    Focuses on developments related to the pharmaceutical industry in the United States, current as of September 30, 2000. Approval of prescription drug called atovaquone/proguanil; Approval of formulation called adapalene.

  • AMCP's formulary submission guidance: keys to making it work at your practice setting. Johnson, Nelda // Formulary;Jan2001, Vol. 36 Issue 1, p42 

    Evaluating outcomes and economic data is an important function for the Formulary Committee to control pharmaceutical costs and improve patient outcomes, Rapid access to relevant, high-quality economic and outcomes analyses has been limited in the past, but a new template for submitting clinical,...

  • Drug and Formulary Trends.  // Formulary;Jan2003, Vol. 38 Issue 1, p28 

    Reports on data related to the pharmaceutical industry in the U.S. as of January 2003. Formulary trends; Total spending on prescription drugs in 2001; Prescription drug spending forecasts for 2002-2011; Pediatric prescription drug spending for 1997-2001.

  • PRICING PRESSURES. Lebowitz, Philip // Pharmaceutical Executive;Mar2002, Vol. 22 Issue 3, p74 

    Focuses on the prescription costs in the U.S. Discussions on the federal government from domestic healthcare; Challenges in the legal aspect of the pharmaceutical industry; Enactment of the Pharmacy Discount Program for extended Medicaid drug benefits. INSET: A Pound of Prevention.

  • Prescription-Event Monitoring in Japan (J-PEM). Kubota, K. // Drug Safety;Apr2002, Vol. 25 Issue 6, p441 

    In prescription-event monitoring in Japan (J-PEM), patients are identified by prescriptions in individual pharmacies where drugs are dispensed. The methodology is somewhat different to that used by the Drug Safety Research Unit in the UK, in that two questionnaires, one to the pharmacist and the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics